The Food and Drug Administration (FDA) is fast-tracking Pfizer-BioNTech’s coronavirus vaccine for final approval with a goal date of January 2022, both companies announced on Friday. On the other side, the political pressure increased to approve the Pfizer-BioNTech vaccine to help win over skeptics.
Moreover, the officials allowed these vaccines under an emergency use authorization amid the COVID-19 pandemic. Both companies are looking for full approval for individuals older than sixteen. Initially, the companies need six months of statistics from kids who received both doses, and the FDA gave temporary approval to the vaccine in May for children ages twelve to fifteen.
The approval from the FDA would give several vaccine doubters peace of mind, creating political pressure to legalize it sooner. Three in ten unvaccinated people said that FDA approval would make it those people more possible to change their minds and receive the dose. However, the process of legalizing a vaccine takes around twelve months, according to Yale’s medical school research. Whereas BioNTech and Pfizer applied for final approval in May.
Some Americans Desired to Wait and See how Vaccine Works in Others
Meanwhile, political pressure to legalize the coronavirus vaccine also increased. In July 2021, former Surgeon General Jerome Adams tweeted that the citizens of the United States are dying while the nation is waiting for the FDA approval of vaccines. Twelve percent of adults said that they decided to wait and see how the COVID-19 vaccine works in others before they tested it, according to a KFF poll released in May.
In that group, people are about as probably to be Republicans and Republicans – even though Republicans are the huge majority of people who will Definitely Not receive the vaccine – and about as possible to be a color of a person or a white. Additionally, the approval from the FDA may have a more positive impact on vaccination rates for individuals who identify as Hispanic and Black, who are overrepresented in the wait and see the group.